The bear market is slamming biotech stocks as hard as any. Shares of the industry-tracking SPDR S&P Biotech ETF (NYSEMKT: XBI) are down by more than 33% so far this year, and its five-year total return is just below breakeven thanks to its dramatic collapse in 2021. With sentiment about biotech so persistently bad, bargain-hunting investors should be on the prowl, as there are bound to be a few diamonds in the rough out there.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting